BPG is committed to discovery and dissemination of knowledge
Minireviews Open Access
Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Clin Oncol. Nov 24, 2026; 17(11): 126700
Published online Nov 24, 2026. doi: 10.5306/wjco.126700
Specific molecular signature redefines the role of posterior and para-aortic (D2 plus) lymphadenectomy in gastric cancer: Rethinking surgical indications
Ludovico Carbone, Daniele Marrelli, Aurora Visani, Franco Roviello, Department of Medicine Surgery and Neuroscience, University of Siena, Siena 53100, Tuscany, Italy
Bina Barbato, Department of Medical Biotechnology, University of Siena, Siena 53100, Tuscany, Italy
Giovanni Corso, Division of Breast Surgery, European Institute of Oncology (IRCCS), Milan 20141, Lombardy, Italy
Giovanni Corso, Department of Oncology and Hemato-oncology, University fo Milan, Milan 20141, Lombardy, Italy
ORCID number: Ludovico Carbone (0000-0003-2862-6788); Daniele Marrelli (0000-0003-2066-1618); Aurora Visani (0009-0002-8832-9953); Giovanni Corso (0000-0002-9269-0146); Franco Roviello (0000-0003-4122-1259).
Author contributions: Marrelli D and Roviello F conceptualised and designed the study; Carbone L and Marrelli D conducted the literature review, did the analysis, interpretation of data and drafted the original manuscript; Visani A collected data; Barbato B, Visani A and Corso G made critical revisions and prepared the draft; Roviello F supervised; all authors approved the submitted version.
AI contribution statement: Figure 8C of this manuscript was edited using AI tools.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Corresponding author: Daniele Marrelli, MD, Doctor, Department of Medicine Surgery and Neuroscience, University of Siena, viale Mario Bracci 11, Siena 53100, Tuscany, Italy. daniele.marrelli@unisi.it
Received: August 11, 2026
Revised: August 28, 2026
Accepted: November 2, 2026
Published online: November 24, 2026
Processing time: 98 Days and 14.2 Hours

Abstract

Posterior and para-aortic (D2 plus) lymphadenectomy is still controversial in gastric cancer surgery, as potential oncologic benefit must be balanced against increased technical complexity. Extended lymph node dissection aims to remove residual regional disease, improve staging, and control locoregional recurrence. This review synthesizes the recent literature on D2 plus in advanced gastric cancer, with particular attention to molecular profiling, response to neoadjuvant therapy, and the role of conversion surgery in oligometastatic disease. D2 plus should not be considered routine but may be evaluated in selected patients with bulky nodes in extragastric regions or isolated para-aortic involvement responding to systemic therapy. Pathological response appears to be the strongest prognostic determinant, and persistent nodal burden after neoadjuvant chemotherapy identifies patients with poor survival. Furthermore, molecular subtypes influence biology and expected benefit from therapy: Microsatellite instable tumors may preserve limited propensity for extensive nodal spread, programmed cell death ligand 1 + expression is associated with sensitivity to immunotherapy, microsatellite stability/epithelial-mesenchymal transition is associated with aggressive behaviour and peritoneal dissemination and may benefit from prophylactic intraperitoneal chemotherapy, while human epidermal growth factor receptor 2+ tumors maintain a more uncertain behaviour. In selected patients with oligometastatic disease, D2 plus may be integrated into a conversion surgery strategy. D2 plus should be adapted to treatment response and biological profiling. Given that residual nodal burden may outweigh primary tumor response, a better understanding of the molecular features of gastric cancer may help identify patients who are most likely to benefit from posterior and para-aortic lymphadenectomy.

Key Words: Stomach cancer; Multimodality approach; Lymph node excision; Translational research; Mismatch repair deficiency; Complications; Robot surgery

Core Tip: D2 plus lymphadenectomy in gastric cancer should be tailored to tumor biology and treatment response. Pathological response to neoadjuvant therapy is the strongest prognostic factor, whereas the emerging molecular characterization (microsatellite instable, programmed cell death ligand 1, epithelial-mesenchymal transition, or human epidermal growth factor receptor 2 status) predicts nodal spread pattern and tumors which likely benefit from extended nodal dissection. In selected oligometastatic patients, para-aortic lymphadenectomy can be integrated into a conversion surgery strategy to achieve complete radicality. Molecular profiling, therefore, represents a promising tool to refine treatment course and surgical indications for lymphadenectomy beyond tumor node metastasis staging alone.



INTRODUCTION

The term D2 plus refers to lymph node dissection beyond the standard D2 field. According to the international guidelines, D2 plus dissection is not routine[1,2]. It can be considered in specific situations, such as No. 8p, No. 12b, No. 12p and No. 13 dissection for duodenal invasion, No. 14v in suspected No. 6 metastasis, and No. 16 dissection in patients with extensive lymph node involvement. Posterior bursectomy might be advisable in cT3/T4 tumors when located in the posterior wall of the stomach, while resection of tumor-specific mesenteries, called “complete mesogastric excision”, is still debated[3,4].

The literature of last 20 years has emphasized the curative role of the dissection of both para-aortic nodes, as a last chance of care in patients with extensive nodal disease, and posterior nodes, particularly No. 12p and No. 13, which are commonly considered the “gatekeepers” of No. 16a2-b1. The reasons supporting the choice of a more extensive lymphadenectomy in selected patients can be summarized into the following three key domains.

The first rationale is anatomical. Gastric cancer spreads mainly through the lymphatic system. Lymph nodes around the stomach have a layered structure: Tumor cells may progress from perigastric nodes to suprapancreatic and celiac nodes. Then, distal tumors primarily move to posterior nodes, while proximal tumors mainly to para-aortic nodes. A relatively better survival of tumors located in the lower-third of the stomach with posterior nodal involvement suggests that these stations may function as “regional” nodes, despite representing advanced lymphatic spread. This pattern explains why lymphadenectomy is not only a staging procedure in gastric cancer, but adequate lymphadenectomy ensures the removal of possible residual regional disease (Figure 1).

Figure 1
Figure 1  Incremental correlation between number of lymph nodes removed (X-axis) and number of lymph metastatic nodes (Y-axis) from our institutional cohort of 589 patients.

The second rationale is biological. A higher number of removed nodes improves pathological staging and refines stage migration. This is particularly true in Western series where D2 plus lymphadenectomy has been associated with a decrease in locoregional tumor recurrence after twenty-four months from operation[5] (Figure 2). Eastern studies confirm that recurrence rate is mostly in stations 16a2 (40%) and 16b1 (60%)[6]. Again, it is plausible that D2 plus lymphadenectomy increases the probability of removing microscopic metastatic disease[7]. Moreover, this may be relevant after neoadjuvant therapy, when radiology can underestimate persistent nodal involvement, ranging from 6% to 33%[8]. In the JCOG0405 trial, patients without evident para-aortic node metastases showed favourable outcomes, whereas those presenting with both bulky N2 and para-aortic nodes experienced significantly worse survival after preoperative chemotherapy[9]. These findings suggest that D2 plus lymphadenectomy may offer the greatest benefit in patients with limited nodal disease, while its role remains less clear in those with more extensive nodal involvement.

Figure 2
Figure 2 Nodal stage migration in non-metastatic gastric cancer: Kaplan-Meier 10-year overall survival according to lymph node retrieval. A: 124 patients undergoing distal or total gastrectomy with fewer than 20 (distal) or 25 (total) lymph nodes examined (P < 0.001); B: 465 with more than 20 nodes retrieved after distal gastrectomy and 25 nodes after total, as recommended by Textbook Outcome in Gastric Surgery, (P < 0.001). Author’s data classified according to the 8th edition of the American Joint Committee on Cancer/Union for International Cancer Control tumor node metastasis classification.

The third rationale is therapeutic. The JCOG9501 trial showed that upfront prophylactic para-aortic dissection does not improve survival in patients without clinically evident para-aortic disease. Therefore, it stated that routine D2 plus dissection cannot be recommended in these patients[10]. However, the same conclusion cannot be closely extended to Western patients presenting a higher incidence of distant lymph node metastases, bulky nodal disease related to diffuse Lauren histotype, or clinically suspected para-aortic nodes who respond to neoadjuvant chemotherapy. In these cases, D2 plus becomes part of a multimodal curative strategy[11]. European data support this selective concept. In the Italian Research Group for Gastric Cancer (GIRCG) cohort, metastases to posterior stations were found in 6.3% of patients and para-aortic metastases in 10.8%. Five-year survival was 17% in patients with positive posterior node and 11% in positive para-aortic node[12]. These results are poor, but in line with Japan Clinical Oncology Group (JCOG) survival[13]. They show that long-term survival is possible in selected patients affected by T3 tumors, where preoperative therapies and enhanced regional nodal clearance may improve disease control. In detail, D2 plus following systemic therapy could be considered in patients having clinical bulky N2 alone without evident para-aortic involvement (prophylactic setting), or in patients showing clinical extensive nodal disease in N3 and radiologically responsive to preoperative therapy (curative setting). In contrast, earlier stages may not justify the additional surgical burden, while in tumors with serosal invasion or positive peritoneal cytology extended dissection alone is unlikely to impact survival due to systemic spread[14].

MOLECULAR PROFILING

The extent of lymphadenectomy has traditionally been based on anatomy. Molecular classification is changing the way we define risk, response, and surgical timing. The Cancer Genome Atlas (TCGA) classification identified four major molecular subtypes of gastric cancer: Epstein-Barr virus (EBV) positive, microsatellite instable (MSI), genomically stable (diffuse type), and chromosomal instability (intestinal type)[15]. The Asian Cancer Research Group (ACRG) classification added prognostic value and showed different recurrence patterns among molecular subgroups, including epithelial-mesenchymal transition (EMT) and mutation in TP53[16] (Table 1 and Figure 3).

Figure 3
Figure 3 Pathological views of gastric cancer. All images are self-generated. A: Microsatellite instable (MSI) MSH2 4 ×; B: MSI MSH6 4 ×; C: MSI MLH1 4 ×; D: MSI PMS2 4 ×; E: Programmed cell death ligand 1 (PD-L1) 4 ×; F: PD-L1 10 ×; G: PD-L1+ 20 ×; H: Epstein-Barr encoding region in situ hybridization (EBER ISH) 4 ×; I: EBER ISH 10 ×; J: EBER ISH 20 ×; K: Human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) 4 ×; L: HER2 IHC 10 ×; M: HER2 IHC 20 ×; N: Epithelial-mesenchymal transition (EMT) + CK8/18 4 ×; O: EMT+ E-cadherin 4 ×; P: EMT+ cluster of differentiation 44 4 ×; Q: EMT+ zinc finger E-box binding homeobox 1 10 ×.
Table 1 Molecular signatures of gastric cancer.
Molecular
Behavior
Recurrence
Notes
MSIBest prognosisLow risk of recurrenceResistant to chemotherapy
PD-L1+Low risk of recurrenceSensitive to immunotherapy
MSS/EMT- (EBV+)Intermediate prognosisMiddle risk of recurrenceSensitive to chemo/immunotherapy
HER2+Intermediate prognosisMiddle risk of recurrenceSensitive to targeted therapy
MSS/EMT+Worst prognosisHigh risk of recurrence
MSI

MSI-high or deficient mismatch repair tumors, accounting for 9%-22% of all tumors, often have a better prognosis and may derive limited benefit from conventional perioperative chemotherapy[17]. Our data showed that MSI status was associated with a lower number of lymph node metastases, a less extensive spread to lymph node stations, and no skip metastases, 0% vs 6.1%, compared with microsatellite stable tumors[18]. This limited propensity for nodal dissemination is thought to reflect an active immune-surveillance mechanism. The high neoantigen burden generated by defective mismatch repair promotes dense cluster of differentiation (CD) 8+ T-cell infiltration of both the tumour and nodes, together with reduced tumour expression of the pro-lymphangiogenic vascular endothelial growth factor-C/vascular endothelial growth factor receptor-3 axis, which together appear to restrain early lymphatic spread[19]. Given their limited propensity for nodal spread and the absence of skip metastases, MSI tumors are unlikely to benefit from extended lymphadenectomy. Conversely, it is plausible to hypothesize that future strategies could favour a less extensive lymphadenectomy (D1 plus), akin to current Eastern clinical practice, which would guarantee equivalent oncological outcomes, at least in early-stage disease. However, this observation is based primarily on retrospective, single-center series and a relatively small MSI subgroup, and its generalizability remains to be established in larger cohorts. Moreover, since MSI tumors derive limited benefit from conventional perioperative chemotherapy, and are more frequent in older patients, upfront surgery or immunotherapy-based strategies may be preferable in selected cases.

PD-L1

Notably, a proportion of these cancers is programmed cell death ligand 1 (PD-L1) positive and may benefit from immunotherapy, especially when human epidermal growth factor receptor 2 (HER2)-negative and with higher combined positive score values[20]. Recently, the MATTERHORN trial showed that adding PD-L1 inhibitor durvalumab to perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) improved event-free survival and pathological complete response[21]. However, significant knowledge gaps remain regarding the mechanisms underlying treatment resistance, as the overall survival benefit appeared to be after the first 12 months, and patients with diffuse-type histology appeared to derive less benefit. Moreover, the impact of immunotherapy on nodal regression, fibrosis and tertiary lymphoid structure formation affecting radiological assessment of disease response, and intraoperative lymph node identification remain incompletely defined. Longer follow-up is warranted to adequately assess its long-term oncological impact in a disease in which recurrences, particularly peritoneal, can occur beyond three years after surgery[22] (Figure 4).

Figure 4
Figure 4 Correlation between number of lymph nodes removed (X-axis) and metastatic (Y-axis). A: In 24 microsatellite instable; B: In 77 microsatellite stability cases. Red lines represent the median number of positive lymph nodes (3 in microsatellite instable and 5 in microsatellite stability). MSI: Microsatellite instable; MSS: Microsatellite stability.
EBV

EBV-positive tumors account for about 10% of cases according to the TCGA, and in the ACRG classification they are “mostly” included in the microsatellite stability (MSS)/EMT- (TP53+) subgroup, which conversely are 20%-25% of all cases[23]. EBV-positive tumors may benefit from standard perioperative chemotherapy, as p53 system increases tumor sensitivity to apoptosis induced by cytotoxic agents such as platinum compounds and fluoropyrimidines[24]. These tumors are also particularly sensitive to immunotherapy because of PD-L1/2 overexpression and immune cell signalling and should be treated as above.

HER2

HER2 overexpression represents approximately 10%-20% of cases. While traditionally associated with more aggressive disease, recent data suggest that HER2-positive tumors may achieve higher pathological response rates to neoadjuvant targeted therapy (e.g., monoclonal antibody and antibody-drug conjugate) in addition to chemotherapy[25]. However, most available evidence derives from metastatic disease, whereas recent retrospective studies have failed to demonstrate a comparable benefit of systemic therapy in non-metastatic cases[26]. In tumors located at the esophago-gastric junction (cardia tumors), the debate over whether extended gastrectomy or distal esophagectomy represents the optimal surgical approach remains open. Importantly, HER2 status does not appear to correlate with a distinct pattern of lymphatic spread, and its overexpression has been recently associated with metastases in lymph nodes in undifferentiated early cancers and locally advanced cases[27,28]. Therefore, it currently does not provide a rationale to modify the extent of lymphadenectomy (Figure 5).

Figure 5
Figure 5 Correlation between number of lymph nodes removed (X-axis) and metastatic (Y-axis). A: In 20 human epidermal growth factor receptor 2 (HER2) +; B: 92 HER2- cases. Red lines represent the median number of positive lymph nodes (2 in HER2+ and 4 in HER2-). HER2: Human epidermal growth factor receptor 2.
EMT

The group of tumors with MSS/EMT+ is also very interesting. EMT is a process where epithelial cells are transformed into cells with mesenchymal phenotypes, characterized by loss of cellular polarity and adhesion[29]. EMT phenotype could be assessed by E-cadherin, CD44 and zinc finger E-box binding homeobox 1 immunohistochemical markers. These patients, accounting for approximately 15% to 30%, had poor prognosis compared with other groups, 17% vs 51%, and when analysing the pattern of relapse, 77% vs 20% of MSS/EMT cases spread to the peritoneum. In these patients, preoperative diagnostic laparoscopy is strongly recommended to detect occult metastases. Resistance to conventional treatments, including chemotherapy, is a major challenge. In patients undergoing upfront surgery, the EMT-positive group showed a strong association with diffuse lymph nodal metastases. However, if this was particularly evident for perigastric nodes, second- and third-tier nodal involvement appears comparable to EMT-negative tumors. Therefore, the extent of lymphadenectomy should be cautiously planned. However, new preoperative therapies targeting EMT may inhibit tumor cell migration and invasion, and reduce fibrosis related to extracellular matrix remodelling. In the future, D2 plus may become response adapted to preoperative therapies. At present, this remains investigational[30]. Increasing data are indicative of a propensity of EMT tumors to spread to the peritoneum, and this could support a potential effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) in young adults.

In summary, new molecular pathways are expected to be included in multidisciplinary treatment of this aggressive disease, in particular when its clinical and therapeutic implications will be further clarified[31] (Figure 6).

Figure 6
Figure 6 Multimodal treatment of locally advanced gastric cancer according to the molecular profiling. Extended lymphadenectomy contraindicated if para-aortic nodal involvement with bulky extragastric nodes or remaining stable after neoadjuvant chemotherapy. 1Indicate a possible role of immunotherapy in combination with chemotherapy in a neoadjuvant setting. MSI: Microsatellite instable; MSS: Microsatellite stability; EMT: Epithelial-mesenchymal transition; EBV: Epstein-Barr virus; PD-L1: Programmed cell death ligand 1; HER: Human epidermal growth factor receptor; HIPEC: Hyperthermic intraperitoneal chemotherapy.
NEOADJUVANT SELECTION

Despite scepticism, with the implementation of neoadjuvant therapy the management of patients with locally advanced gastric cancer has profoundly changed, and the evidence that has so far constituted the cornerstone of gastric cancer surgery must now be reconsidered and critically re-evaluated.

Curative strategy

The strongest indication is extensive nodal disease that responds to preoperative therapy. Eastern authors generally classify positive No. 16 as metastatic disease. These patients, even in the presence of cN2+ disease, are typically treated only with S-1-based therapy. However, JCOG0405 reported over 50% 5-year overall survival in patients with isolated para-aortic lymph node metastases who underwent para-aortic dissection after chemotherapy[10]. Subsequent JCOG studies tested more intensive regimens, including docetaxel-based combinations, with the aim of improving pathological response[32,33]. In these cohorts, histological regression and especially post-treatment nodal status (ypN-) emerged as the most powerful prognostic determinants after para-aortic node dissection. In contrast, patients with persistent pathologically positive nodes after neoadjuvant therapy (ypN3+) had a consistently poor prognosis, regardless of primary tumor regression, indicating that residual nodal burden may override primary tumor response as a survival determinant[34,35].

The Western setting is different, as perioperative chemotherapy, mainly docetaxel or FLOT-based, is the standard for most locally advanced resectable disease[36,37]. In this case, D2 plus should be discussed after radiological response assessment. A patient with initially suspicious para-aortic nodes (cN3+) that disappear or markedly shrink after chemotherapy (ycN-) is different from a patient with persistent or progressive para-aortic disease (ycN3+). The first may be considered for curative D2 plus lymphadenectomy, while the second should usually continue systemic treatments allowing for subsequent conversion surgery or pursuing to a palliative treatment. The recent integration of immunotherapy into neoadjuvant treatment strategies might increase the proportion of responders in future and potentially enhance the benefit of super-extended lymphadenectomy with the aim of achieving better disease control[21]. An experience from our center identified a subgroup potentially benefiting from D2 plus: Patients achieving R0 resection with ypN0-N2+ disease reached 5-year survival rates of 53%-67%, whereas those with pathologically positive posterior or para-aortic nodes (ypN3+) shared a similarly dismal prognosis, less than 8%. It suggests that persistent high nodal burden after chemotherapy reflects systemic rather than locoregional failure (Table 1)[38].

If the key point is selection, two major limitations of the current literature should be highlighted. One is the absence of a standardized definition of bulky nodes, with studies adopting heterogeneous size-based criteria such as a longest axis greater than or equal to 10 mm, a short-axis diameter greater than or equal to 8 mm, or nodal conglomerates greater than or equal to 3 cm or two adjacent nodes greater than or equal to 1.5 cm[39]. The other issue is the heterogeneity in assessment tools used to evaluate response to neoadjuvant therapy[40], including clinical criteria such as response evaluation criteria in solid tumors or single-parameter measurements, and pathological tumor regression grade and JCOG histological criteria[41,42], which complicate the interpretation and comparison of oncological outcomes across studies. In the absence of a validated integrated algorithm, future studies should aim to develop and validate a standardized strategy integrating radiological and pathological response criteria to guide the selection of candidates for D2-plus lymphadenectomy.

Prophylactic strategy

A different scenario is represented by patients at high-risk nodal biology, without preoperative evidence of para-aortic metastases (cN3-). This includes diffuse or poorly cohesive histology, proximal tumors, cT3/T4 disease, bulky N2 disease, distal tumors with bulky No. 6 involvement, and tumors invading the duodenum[43]. The JCOG2212A trial states that, in patients with bulky extragastric nodes (cN2+), prophylactic D2 plus can be considered, as neoadjuvant chemotherapy can induce a partial obliteration of lymphatic pathways, potentially masking residual tumor spread or redirecting lymphatic drainage beyond conventional D2 boundaries[44]. JCOG0405 reported a 5-year overall survival of 68% in patients with bulky N2 alone. Anyway, other series from Eastern Asia suggest that patients achieving a “good” histological response showed lower recurrence rates after D2 plus compared to standard D2 dissection, 27% vs 70%, whereas “poor” responders exhibited persistently high recurrence rates despite more extensive surgery, indicating that chemoresistant nodal biology cannot be compensated by extended surgery alone[45].

CONVERSION SURGERY AND OLIGOMETASTATIC DISEASE

Oligometastatic gastric cancer is not simply stage IV disease with a small tumor burden. It is a dynamic condition, between locally restricted and widespread cancer[46]. It should be defined after systemic therapy, based on response, stability, and the possibility of complete macroscopic clearance. Recent Italian (Bertinoro) consensus statements define oligometastatic gastric cancer as disease limited to selected sites, including para-aortic nodes[47]. The Korea International Gastric Cancer consensus, based on Yoshida classification[48], similarly supports conversion surgery only in patients with favourable response to systemic therapy and limited metastatic burden, such as one extra-regional lymph node station or very limited organ disease[49] (Table 2).

Table 2 Definitions of oligometastatic disease.
Consensus
Study
Appropriate candidates for conversion therapy
OMECKroese et al[50]Limited to 1 organ with ≤ 3 metastases, or involvement of 1 extra-regional lymph node station
KINGCAKim et al[54]Limited to 1 organ, or involvement of 1 extra-regional lymph node station or positive peritoneal cytology (Yoshida 1)
BertinoroMorgagni et al[52]≤ 3 resectable liver or lung metastases (excluded bones), or involvement of para-aortic nodes, or peritoneal cancer index ≤ 6

This distinction is essential. Upfront gastrectomy for metastatic disease is not justified. REGATTA showed no survival benefit for gastrectomy followed by chemotherapy compared with chemotherapy alone in patients with a single non-curable factor[50]. In contrast, AIO FLOT3 suggested that selected patients with limited metastatic disease may benefit from chemotherapy followed by surgery when complete resection is feasible[51]. Therefore, D2 plus in oligometastatic disease should be considered as part of conversion surgery. However, the RENAISSANCE trial (AIO FLOT5) provides important caution against a generalized application of this strategy[52]. It did not demonstrate an overall survival benefit from adding surgery to systemic therapy in patients with metastatic gastric or gastroesophageal junction cancer, whereas exploratory analyses suggested a potential benefit in patients with isolated retroperitoneal lymph node metastases, supporting a highly selective approach to conversion surgery.

Recent Western data also support this selective strategy. In a retrospective cohort of oligometastatic gastric cancer patients treated with D2 plus after chemotherapy, the procedure was feasible and associated with low morbidity and mortality. Pathological positive nodes in the posterior and para-aortic stations remained frequent, showing that even after systemic therapy residual disease is not negligible[12,38].

In practical terms, D2 plus combined with additional peritonectomy and HIPEC may be justified when the goal is to achieve R0 resection of the primary tumor and all known disease, including nodal metastases, after effective downstaging from systemic or locoregional chemotherapies[53] (Figure 7).

Figure 7
Figure 7 Potential treatment of oligometastatic gastric cancer. HIPEC: Hyperthermic intraperitoneal chemotherapy; PIPAC: Pressurized intra-peritoneal aerosol chemotherapy.
COMPLICATIONS AND ROBOTIC APPROACH

A final critical concern when considering super-extended lymphadenectomy beyond D2 is the balance between potential oncologic benefit and increased surgical risk. Experienced surgeons have demonstrated that mortality differences may be minimized, suggesting that surgical expertise is a key determinant of safety[54]. Randomized trials such as JCOG9501 and other multi-center studies confirmed that, although postoperative complications tend to be slightly more frequent after extended dissections, approximately 20%-28% vs 21% for D2, differences in mortality are generally not statistically significant. Importantly, factors such as splenectomy, pancreatic resection, excessive blood loss, and patient comorbidities have been identified as independent predictors of complications[10,55,56].

With the widespread adoption of neoadjuvant therapy, surgeons are increasingly required to perform complete lymphadenectomy in the setting of tissue sclerosis. In our experience, chemotherapy-induced fibrosis is particularly pronounced in the peri-pancreatic and retroperitoneal areas. Consistently, neoadjuvant treatment appears to increase the technical complexity of super-extended lymphadenectomy, potentially leading to higher intraoperative blood loss, mainly due to chemotherapy-induced fibrosis surrounding lymphatic and vascular structures[57]. Nevertheless, available evidence suggests that D2 plus is feasible, without a clear increase in mortality. Reported morbidity rates are generally acceptable and comparable to upfront surgery in experienced centers, although with a trend toward higher overall complication rates and increased need for intraoperative meticulousness. Generally, severe complications are relatively infrequent, 9%-11%[38,58] (Figure 8).

Figure 8
Figure 8 Tissue sclerosis around major vessels after neoadjuvant chemotherapy. A and B: Own intraoperative frame; C: Schematic image. IVC: Inferior vein cava; Ao: Aorta; LRV: Left renal vein.

Importantly, the number of removed lymph nodes remains a main surrogate of surgical quality and an independent prognostic factor in gastric cancer. Italian series showed a mean of 39 lymph nodes removed even after neoadjuvant chemotherapy, comparable to that reported in upfront surgery cohorts, 41 in the GIRCG multi-center study[12,38]. Nevertheless, posterior and para-aortic lymphadenectomy is technically demanding. It consists of deep dissection around the pancreas, portal structures, hepatoduodenal ligament, duodenum, and major retroperitoneal vessels.

Numerous proficient laparoscopic surgeons have adopted robotic platforms for the treatment of gastric cancer. Recent literature suggests that robotic gastrectomy can achieve outcomes comparable to laparoscopic gastrectomy, with adequate lymph node retrieval and potential advantages when fat or fibrosis make tissue planes less clear[59,60]. Exposure of No. 8p (posterior to the common hepatic artery) and No. 13 (posterior surface of the pancreatic head) often requires careful mobilization of the duodenum and pancreatic head, and increases the risk of pancreatic injury, biliary leakage, and retroperitoneal infectious complications. The robotic platform may offer technical advantages in reducing the incidence of pancreatic fistula during the suprapancreatic dissection[61]. Dissection of No. 16 is associated with a non-negligible risk of massive haemorrhage and lymphatic leakage. Therefore, it is essential that the surgeon adheres to the fundamental surgical principles established in open surgery, maintaining dissection strictly within the periadventitial plane and mobilising the nodal packet en bloc off the great vessels rather than working through the tissue, while appropriately adapting them to the specific characteristics of the robotic platform. Moreover, careful identification and preservation of the neural plane surrounding the celiac ganglion and splanchnic nerve trunks may contribute to reducing postoperative autonomic dysfunction[62]. Overall, reduced intraoperative tissue manipulation and attenuation of the postoperative inflammatory response may translate into faster recovery and earlier initiation of adjuvant chemotherapy. A large matched study reported a nearly half lower rate of postoperative complications with the robotic approach, supporting the potential role of robotic assistance after neoadjuvant therapy[63]. However, the available evidence remains limited to non-randomized studies, predominantly from East Asian centers. Long-term data support oncological safety in advanced gastric cancer when performed by experienced surgeons.

CONCLUSION

D2 plus should be adapted primarily to treatment response, disease distribution and nodal biology, which currently represent the most robust determinants for patient selection. Nevertheless, the extent of lymphadenectomy in gastric cancer is increasingly influenced not only by anatomy but also by tumor biology and the potential for improved long-term survival. However, much of the evidence derives from retrospective, non-randomised series, which are subject to selection bias and limit causal inference. Thus, the integration of molecular and biological features into surgical treatment remains investigational and requires prospective validation. Furthermore, circulating tumor DNA (ctDNA) has been shown to track pathological response to chemotherapy, with persistently detectable ctDNA identifying patients at markedly higher risk of recurrence despite apparent radiological downstaging[64]. Because residual ctDNA plausibly reflects occult systemic and nodal micro-metastatic disease, liquid biopsy could help identify patients who may benefit from more extensive nodal dissection. This specific application is still investigational. Claudin 18.2 has emerged as a further clinically actionable target, with the anti-claudin 18.2 monoclonal antibody approved in combination with chemotherapy for HER2- cancers[65]. However, its support in lymphadenectomy choice remains undefined. Conversely, CT-based deep-learning radiomic models have been developed to preoperatively estimate the number of metastatic lymph node and, potentially, predict nodal regression to neoadjuvant chemotherapy[66], ultimately complementing rather than replacing pathological staging. Finally, the emerging concept of oligometastatic disease is reshaping the surgical role of D2 plus, which should be considered mainly within conversion strategies for patients with responsive para-aortic or limited metastatic disease. Further prospective studies are needed to standardize selection criteria, validate molecular markers of response to preoperative treatments, chemo- and immunotherapy, which could in principle be extended to predict nodal, rather than only primary tumour, regression in the era of perioperative chemo-immunotherapy.

ACKNOWLEDGEMENTS

The authors gratefully acknowledge the Difesa Attività Segugistica (DAS) (Tuscany, Italy) for its sensitivity throughout this research and support awarded in recognition of the group’s scientific activity.

References
1.  Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2025 (7th edition). Gastric Cancer. 2026;29:271-299.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 1]  [Cited by in RCA: 45]  [Article Influence: 45.0]  [Reference Citation Analysis (1)]
2.  Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, Vogel A, Smyth EC; ESMO Guidelines Committee. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:1005-1020.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 1159]  [Cited by in RCA: 1167]  [Article Influence: 291.8]  [Reference Citation Analysis (19)]
3.  De Manzoni G, Marrelli D, Baiocchi GL, Morgagni P, Saragoni L, Degiuli M, Donini A, Fumagalli U, Mazzei MA, Pacelli F, Tomezzoli A, Berselli M, Catalano F, Di Leo A, Framarini M, Giacopuzzi S, Graziosi L, Marchet A, Marini M, Milandri C, Mura G, Orsenigo E, Quagliuolo V, Rausei S, Ricci R, Rosa F, Roviello G, Sansonetti A, Sgroi G, Tiberio GA, Verlato G, Vindigni C, Rosati R, Roviello F. The Italian Research Group for Gastric Cancer (GIRCG) guidelines for gastric cancer staging and treatment: 2015. Gastric Cancer. 2017;20:20-30.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 155]  [Cited by in RCA: 157]  [Article Influence: 17.4]  [Reference Citation Analysis (11)]
4.  Meng X, Wang L, Liu G, Zhang J, Wang Y, Yang D, Zheng G, Zhang T, Zheng Z, Zhao Y. D2 lymphadenectomy with complete mesogastrium excision vs. conventional D2 gastrectomy for advanced gastric cancer. Chin Med J (Engl). 2022;135:1223-1230.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 9]  [Cited by in RCA: 9]  [Article Influence: 2.3]  [Reference Citation Analysis (1)]
5.  de Manzoni G, Verlato G, Bencivenga M, Marrelli D, Di Leo A, Giacopuzzi S, Cipollari C, Roviello F. Impact of super-extended lymphadenectomy on relapse in advanced gastric cancer. Eur J Surg Oncol. 2015;41:534-540.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 30]  [Cited by in RCA: 36]  [Article Influence: 3.3]  [Reference Citation Analysis (8)]
6.  Chang JS, Kim KH, Yoon HI, Hyung WJ, Rha SY, Kim HS, Lee YC, Lim JS, Noh SH, Koom WS. Locoregional relapse after gastrectomy with D2 lymphadenectomy for gastric cancer. Br J Surg. 2017;104:877-884.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 18]  [Cited by in RCA: 32]  [Article Influence: 3.6]  [Reference Citation Analysis (4)]
7.  Kinami S, Saito H, Takamura H. Significance of Lymph Node Metastasis in the Treatment of Gastric Cancer and Current Challenges in Determining the Extent of Metastasis. Front Oncol. 2021;11:806162.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 49]  [Cited by in RCA: 48]  [Article Influence: 12.0]  [Reference Citation Analysis (1)]
8.  Douridas GN, Pierrakakis SK. Is There Any Role for D3 Lymphadenectomy in Gastric Cancer? Front Surg. 2018;5:27.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 10]  [Cited by in RCA: 8]  [Article Influence: 1.0]  [Reference Citation Analysis (1)]
9.  Tsuburaya A, Mizusawa J, Tanaka Y, Fukushima N, Nashimoto A, Sasako M; Stomach Cancer Study Group of the Japan Clinical Oncology Group. Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br J Surg. 2014;101:653-660.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 283]  [Cited by in RCA: 257]  [Article Influence: 21.4]  [Reference Citation Analysis (13)]
10.  Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, Hiratsuka M, Tsujinaka T, Kinoshita T, Arai K, Yamamura Y, Okajima K; Japan Clinical Oncology Group. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med. 2008;359:453-462.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 796]  [Cited by in RCA: 751]  [Article Influence: 41.7]  [Reference Citation Analysis (12)]
11.  Katayama H, Tsuburaya A, Mizusawa J, Nakamura K, Katai H, Imamura H, Nashimoto A, Fukushima N, Sano T, Sasako M. An integrated analysis of two phase II trials (JCOG0001 and JCOG0405) of preoperative chemotherapy followed by D3 gastrectomy for gastric cancer with extensive lymph node metastasis. Gastric Cancer. 2019;22:1301-1307.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 15]  [Cited by in RCA: 32]  [Article Influence: 4.6]  [Reference Citation Analysis (2)]
12.  Marrelli D, Ferrara F, Giacopuzzi S, Morgagni P, Di Leo A, De Franco L, Pedrazzani C, Saragoni L, De Manzoni G, Roviello F. Incidence and Prognostic Value of Metastases to "Posterior" and Para-aortic Lymph Nodes in Resectable Gastric Cancer. Ann Surg Oncol. 2017;24:2273-2280.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 19]  [Cited by in RCA: 20]  [Article Influence: 2.2]  [Reference Citation Analysis (10)]
13.  Yoshida M, Ohtsu A, Boku N, Miyata Y, Shirao K, Shimada Y, Hyodo I, Koizumi W, Kurihara M, Yoshida S, Yamamoto S. Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the Japan Clinical Oncology Group (JCOG) study. Jpn J Clin Oncol. 2004;34:654-659.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 86]  [Cited by in RCA: 82]  [Article Influence: 3.7]  [Reference Citation Analysis (1)]
14.  Bencivenga M, Verlato G, Mengardo V, Scorsone L, Sacco M, Torroni L, Giacopuzzi S, de Manzoni G. Is There Any Role for Super-Extended Limphadenectomy in Advanced Gastric Cancer? Results of an Observational Study from a Western High Volume Center. J Clin Med. 2019;8:1799.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 9]  [Cited by in RCA: 7]  [Article Influence: 1.0]  [Reference Citation Analysis (11)]
15.  Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202-209.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 5694]  [Cited by in RCA: 5314]  [Article Influence: 442.8]  [Reference Citation Analysis (18)]
16.  Cristescu R, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS, Liu J, Yue YG, Wang J, Yu K, Ye XS, Do IG, Liu S, Gong L, Fu J, Jin JG, Choi MG, Sohn TS, Lee JH, Bae JM, Kim ST, Park SH, Sohn I, Jung SH, Tan P, Chen R, Hardwick J, Kang WK, Ayers M, Hongyue D, Reinhard C, Loboda A, Kim S, Aggarwal A. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015;21:449-456.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 1838]  [Cited by in RCA: 1743]  [Article Influence: 158.5]  [Reference Citation Analysis (13)]
17.  Liu B, Shen C, Yin X, Jiang T, Han Y, Yuan R, Yin Y, Cai Z, Zhang B. Perioperative chemotherapy for gastric cancer patients with microsatellite instability or deficient mismatch repair: A systematic review and meta-analysis. Cancer. 2025;131:e35831.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 9]  [Reference Citation Analysis (1)]
18.  Ooki A, Osumi H, Yoshino K, Yamaguchi K. Potent therapeutic strategy in gastric cancer with microsatellite instability-high and/or deficient mismatch repair. Gastric Cancer. 2024;27:907-931.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 47]  [Cited by in RCA: 55]  [Article Influence: 27.5]  [Reference Citation Analysis (1)]
19.  Tsai CY, Tai TS, Huang SC, Chen TH, Hsu JT, Yeh CN, Lai YC, Lin G, Yeh TS. Overestimation of clinical N-staging in microsatellite instable gastric cancers is associated with VEGF-C signaling and CD8+ T-cell dynamics. Oncologist. 2025;30:oyae288.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 2]  [Reference Citation Analysis (0)]
20.  Cho Y, Ahn S, Kim KM. PD-L1 as a Biomarker in Gastric Cancer Immunotherapy. J Gastric Cancer. 2025;25:177-191.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 20]  [Cited by in RCA: 34]  [Article Influence: 34.0]  [Reference Citation Analysis (0)]
21.  Janjigian YY, Al-Batran SE, Wainberg ZA, Muro K, Molena D, Van Cutsem E, Hyung WJ, Wyrwicz L, Oh DY, Omori T, Moehler M, Garrido M, Oliveira SCS, Liberman M, Oliden VC, Smyth EC, Stein A, Bilici M, Alvarenga ML, Kozlov V, Rivera F, Kawazoe A, Serrano O, Heilbron E, Negro A, Kurland JF, Tabernero J; MATTERHORN Investigators. Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer. N Engl J Med. 2025;393:217-230.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 167]  [Cited by in RCA: 268]  [Article Influence: 268.0]  [Reference Citation Analysis (2)]
22.  Pettigrew MF, Coburn NG, Woo Y, Porembka MR. The Landmark Series: Neoadjuvant Therapy for Patients with Resectable Gastroesophageal Junction Adenocarcinomas. Ann Surg Oncol. 2026;33:9237-9248.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 1]  [Reference Citation Analysis (0)]
23.  Smyth EC, Wotherspoon A, Peckitt C, Gonzalez D, Hulkki-Wilson S, Eltahir Z, Fassan M, Rugge M, Valeri N, Okines A, Hewish M, Allum W, Stenning S, Nankivell M, Langley R, Cunningham D. Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial. JAMA Oncol. 2017;3:1197-1203.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 447]  [Cited by in RCA: 428]  [Article Influence: 47.6]  [Reference Citation Analysis (6)]
24.  Camargo MC, Kim WH, Chiaravalli AM, Kim KM, Corvalan AH, Matsuo K, Yu J, Sung JJ, Herrera-Goepfert R, Meneses-Gonzalez F, Kijima Y, Natsugoe S, Liao LM, Lissowska J, Kim S, Hu N, Gonzalez CA, Yatabe Y, Koriyama C, Hewitt SM, Akiba S, Gulley ML, Taylor PR, Rabkin CS. Improved survival of gastric cancer with tumour Epstein-Barr virus positivity: an international pooled analysis. Gut. 2014;63:236-243.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 317]  [Cited by in RCA: 306]  [Article Influence: 25.5]  [Reference Citation Analysis (3)]
25.  Arigami T, Matsushita D, Okubo K, Sasaki K, Tsuruda Y, Kita Y, Mori S, Yanagita S, Uenosono Y, Kurahara H, Ohtsuka T. Prognostic Significance of HER2 Expression for Gastric Cancer With Clinically Para-aortic Lymph Node Metastasis. Anticancer Res. 2021;41:3099-3107.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 1]  [Cited by in RCA: 1]  [Article Influence: 0.2]  [Reference Citation Analysis (0)]
26.  Piccioni SA, Costantini M, Petrioli R, Bagnacci G, Ferrara D, Andreucci E, Carbone L, Ongaro A, Calomino N, Sandini M, Mazzei MA, Roviello F, Marrelli D. Impact of HER2 and microsatellite instability status on response to neoadjuvant/conversion therapy and survival in patients with gastric cancer. Eur J Cancer Prev. 2026;35:66-77.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 8]  [Cited by in RCA: 13]  [Article Influence: 13.0]  [Reference Citation Analysis (1)]
27.  Ieni A, Barresi V, Caltabiano R, Caleo A, Bonetti LR, Lanzafame S, Zeppa P, Caruso RA, Tuccari G. Discordance rate of HER2 status in primary gastric carcinomas and synchronous lymph node metastases: a multicenter retrospective analysis. Int J Mol Sci. 2014;15:22331-22341.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 24]  [Cited by in RCA: 33]  [Article Influence: 2.8]  [Reference Citation Analysis (0)]
28.  Han S, Park S, An J, Yang JY, Chung JW, Kim YJ, Kim KO, Park DK, Kwon KA, Lee WK, Nam S, Kim JH. HER2 as a potential biomarker of lymph node metastasis in undifferentiated early gastric cancer. Sci Rep. 2020;10:5270.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 5]  [Cited by in RCA: 11]  [Article Influence: 1.8]  [Reference Citation Analysis (0)]
29.  Carbone L, Incognito GG, Incognito D, Nibid L, Caruso G, Berretta M, Taffon C, Palumbo M, Perrone G, Roviello F, Marrelli D. Clinical implications of epithelial-to-mesenchymal transition in cancers which potentially spread to peritoneum. Clin Transl Oncol. 2025;27:2838-2851.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 9]  [Reference Citation Analysis (0)]
30.  Marrelli D, Marano L, Ambrosio MR, Carbone L, Spagnoli L, Petrioli R, Ongaro A, Piccioni S, Fusario D, Roviello F. Immunohistochemical Markers of the Epithelial-to-Mesenchymal Transition (EMT) Are Related to Extensive Lymph Nodal Spread, Peritoneal Dissemination, and Poor Prognosis in the Microsatellite-Stable Diffuse Histotype of Gastric Cancer. Cancers (Basel). 2022;14:6023.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 10]  [Cited by in RCA: 9]  [Article Influence: 2.3]  [Reference Citation Analysis (0)]
31.  Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer. CA Cancer J Clin. 2021;71:264-279.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 1167]  [Cited by in RCA: 1294]  [Article Influence: 258.8]  [Reference Citation Analysis (32)]
32.  Ito S, Sano T, Mizusawa J, Takahari D, Katayama H, Katai H, Kawashima Y, Kinoshita T, Terashima M, Nashimoto A, Nakamori M, Onaya H, Sasako M. A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy with D2 plus para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002. Gastric Cancer. 2017;20:322-331.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 100]  [Cited by in RCA: 100]  [Article Influence: 11.1]  [Reference Citation Analysis (5)]
33.  Takahari D, Ito S, Mizusawa J, Katayama H, Terashima M, Sasako M, Morita S, Nomura T, Yamada M, Fujiwara Y, Kimura Y, Ikeda A, Kadokawa Y, Sano T; Stomach Cancer Study Group of the Japan Clinical Oncology Group. Long-term outcomes of preoperative docetaxel with cisplatin plus S-1 therapy for gastric cancer with extensive nodal metastasis (JCOG1002). Gastric Cancer. 2020;23:293-299.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 40]  [Cited by in RCA: 38]  [Article Influence: 6.3]  [Reference Citation Analysis (1)]
34.  Endo S, Ikenaga M, Yamada T, Tamura S, Sasaki YO. Prognostic Factors for Para-aortic Lymph Node Dissection After Neoadjuvant Chemotherapy for Gastric Cancer. Anticancer Res. 2020;40:2351-2357.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 1]  [Cited by in RCA: 3]  [Article Influence: 0.5]  [Reference Citation Analysis (0)]
35.  Wada T, Yoshikawa T, Sekine S, Kamiya A, Hayashi T, Otsuki S, Yamagata Y, Katai H. Pathological complete response at the para-aortic nodes as a possible surrogate endpoint in gastric cancer surgery with para-aortic node dissection after neoadjuvant chemotherapy. Eur J Surg Oncol. 2022;48:333-338.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 3]  [Reference Citation Analysis (1)]
36.  Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, Kopp HG, Mayer F, Haag GM, Luley K, Lindig U, Schmiegel W, Pohl M, Stoehlmacher J, Folprecht G, Probst S, Prasnikar N, Fischbach W, Mahlberg R, Trojan J, Koenigsmann M, Martens UM, Thuss-Patience P, Egger M, Block A, Heinemann V, Illerhaus G, Moehler M, Schenk M, Kullmann F, Behringer DM, Heike M, Pink D, Teschendorf C, Löhr C, Bernhard H, Schuch G, Rethwisch V, von Weikersthal LF, Hartmann JT, Kneba M, Daum S, Schulmann K, Weniger J, Belle S, Gaiser T, Oduncu FS, Güntner M, Hozaeel W, Reichart A, Jäger E, Kraus T, Mönig S, Bechstein WO, Schuler M, Schmalenberg H, Hofheinz RD; FLOT4-AIO Investigators. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393:1948-1957.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 2158]  [Cited by in RCA: 2038]  [Article Influence: 291.1]  [Reference Citation Analysis (23)]
37.  Kang YK, Kim HD, Yook JH, Park YK, Lee JS, Kim YW, Kim JY, Ryu MH, Rha SY, Chung IJ, Kim IH, Oh SC, Park YS, Cheong JH, Jeong O, Heo MH, Kim HK, Park C, Yoo CH, Kang SY, Zang DY, Jang YJ, Sul JY, Kim JG, Kim BS, Beom SH, Hwang JE, Ryu SW, Kook MC, Ryoo BY, Kim H, Yoo MW, Lee NS, Lee SH, Noh SH. Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY. J Clin Oncol. 2024;42:2961-2965.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 47]  [Cited by in RCA: 46]  [Article Influence: 23.0]  [Reference Citation Analysis (1)]
38.  Marrelli D, Piccioni SA, Carbone L, Petrioli R, Costantini M, Malagnino V, Bagnacci G, Rizzoli G, Calomino N, Piagnerelli R, Mazzei MA, Roviello F. Posterior and Para-Aortic (D2plus) Lymphadenectomy after Neoadjuvant/Conversion Therapy for Locally Advanced/Oligometastatic Gastric Cancer. Cancers (Basel). 2024;16:1376.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 30]  [Cited by in RCA: 30]  [Article Influence: 15.0]  [Reference Citation Analysis (0)]
39.  Loch FN, Beyer K, Kreis ME, Kamphues C, Rayya W, Schineis C, Jahn J, Tronser M, Elsholtz FHJ, Hamm B, Reiter R. Diagnostic performance of Node Reporting and Data System (Node-RADS) for regional lymph node staging of gastric cancer by CT. Eur Radiol. 2024;34:3183-3193.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 3]  [Cited by in RCA: 58]  [Article Influence: 29.0]  [Reference Citation Analysis (0)]
40.  Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 24191]  [Cited by in RCA: 23618]  [Article Influence: 1389.3]  [Reference Citation Analysis (33)]
41.  Kurokawa Y, Shibata T, Sasako M, Sano T, Tsuburaya A, Iwasaki Y, Fukuda H. Validity of response assessment criteria in neoadjuvant chemotherapy for gastric cancer (JCOG0507-A). Gastric Cancer. 2014;17:514-521.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 62]  [Cited by in RCA: 69]  [Article Influence: 5.3]  [Reference Citation Analysis (1)]
42.  Nakamura K, Kuwata T, Shimoda T, Mizusawa J, Katayama H, Kushima R, Taniguchi H, Sano T, Sasako M, Fukuda H. Determination of the optimal cutoff percentage of residual tumors to define the pathological response rate for gastric cancer treated with preoperative therapy (JCOG1004-A). Gastric Cancer. 2015;18:597-604.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 34]  [Cited by in RCA: 32]  [Article Influence: 2.9]  [Reference Citation Analysis (3)]
43.  Mengardo V, Bencivenga M, Weindelmayer J, Pavarana M, Giacopuzzi S, de Manzoni G. Para-aortic lymphadenectomy in surgery for gastric cancer: current indications and future perspectives. Updates Surg. 2018;70:207-211.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 5]  [Cited by in RCA: 8]  [Article Influence: 1.0]  [Reference Citation Analysis (0)]
44.  Wada T, Yokoyama M, Ito S, Hashimoto T, Kawabata K, Ehara K, Nomura T, Aizawa M, Kawabata R, Takahari D, Sasako M, Tsuburaya A, Sano T, Terashima M, Boku N, Kurokawa Y, Yoshikawa T. Therapeutic value of para-aortic lymph node dissection in gastric cancer with extensive lymph node metastasis: Integrated analysis of three phase II trials (JCOG2212A). J Clin Oncol. 2025;43:419-419.  [PubMed]  [DOI]  [Full Text]
45.  Kenichiro F, Matsumoto Y, Soneda W, Koseki Y, Fujiya K, Tanizawa Y, Bando E. Prophylactic para-aortic lymph node dissection after neoadjuvant chemotherapy for gastric cancer with bulky lymph node metastasis. J Clin Oncol. 2024;42:344-344.  [PubMed]  [DOI]  [Full Text]
46.  Kroese TE, Bronzwaer S, van Rossum PSN, Schoppman SF, Deseyne PRAJ, van Cutsem E, Haustermans K, Nafteux P, Thomas M, Obermannova R, Mortensen HR, Nordsmark M, Pfeiffer P, Elme A, Adenis A, Piessen G, Bruns CJ, Lordick F, Gockel I, Moehler M, Gani C, Liakakos T, Reynolds JV, Morganti AG, Rosati R, Castoro C, Cellini F, D'Ugo D, Roviello F, Bencivenga M, de Manzoni G, van Berge Henegouwen MI, Hulshoff MCCM, van Dieren J, Vollebergh M, van Sandick JW, Jeene P, Muijs C, Slingerland M, Voncken FEM, Hartgrink H, Creemers GJ, van der Sangen MJC, Nieuwenhuijzen GAP, Berbee M, Verheij M, Wijnhoven B, Beerepoot LV, Mohammad NH, Mook S, Ruurda JP, Kolodziejczyk P, Polkowski WP, Wyrwicz L, Alsina M, Tabernero J, Pera M, Kanonnikoff TF, Cervantes A, Nilsson M, Monig S, Wagner AD, Guckenberger M, Griffiths EA, Smyth E, Hanna GB, Markar S, Chaudry MA, Hawkins MA, Cheong E, van Laarhoven HWM, van Hillegersberg R; OMEC collaborators. European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4). Eur J Cancer. 2024;204:114062.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 48]  [Reference Citation Analysis (0)]
47.  Morgagni P, Bencivenga M, Carneiro F, Cascinu S, Derks S, Di Bartolomeo M, Donohoe C, Eveno C, Gisbertz S, Grimminger P, Gockel I, Grabsch H, Kassab P, Langer R, Lonardi S, Maltoni M, Markar S, Moehler M, Marrelli D, Mazzei MA, Melisi D, Milandri C, Moenig PS, Mostert B, Mura G, Polkowski W, Reynolds J, Saragoni L, Van Berge Henegouwen MI, Van Hillegersberg R, Vieth M, Verlato G, Torroni L, Wijnhoven B, Tiberio GAM, Yang HK, Roviello F, de Manzoni G; Bertinoro Workshop Working Group. International consensus on the management of metastatic gastric cancer: step by step in the foggy landscape : Bertinoro Workshop, November 2022. Gastric Cancer. 2024;27:649-671.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 21]  [Cited by in RCA: 27]  [Article Influence: 13.5]  [Reference Citation Analysis (2)]
48.  Yoshida K, Yamaguchi K, Okumura N, Tanahashi T, Kodera Y. Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification. Gastric Cancer. 2016;19:329-338.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 291]  [Cited by in RCA: 290]  [Article Influence: 29.0]  [Reference Citation Analysis (1)]
49.  Kim TH, Uyama I, Rha SY, Bencivenga M, An J, Wyrwicz L, Koo DH, van Hillegersberg R, Lee KW, Li G, Yoshikawa T, Badgwell B, Lorenzen S, Kim IH, Lee IS, Han HS, Hoon H. Conversion Therapy for Stage IV Gastric Cancer: Report From the Expert Consensus Meeting at KINGCA WEEK 2024. J Gastric Cancer. 2025;25:133-152.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 6]  [Cited by in RCA: 11]  [Article Influence: 11.0]  [Reference Citation Analysis (4)]
50.  Fujitani K, Yang HK, Mizusawa J, Kim YW, Terashima M, Han SU, Iwasaki Y, Hyung WJ, Takagane A, Park DJ, Yoshikawa T, Hahn S, Nakamura K, Park CH, Kurokawa Y, Bang YJ, Park BJ, Sasako M, Tsujinaka T; REGATTA study investigators. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016;17:309-318.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 587]  [Cited by in RCA: 545]  [Article Influence: 54.5]  [Reference Citation Analysis (12)]
51.  Al-Batran SE, Homann N, Pauligk C, Illerhaus G, Martens UM, Stoehlmacher J, Schmalenberg H, Luley KB, Prasnikar N, Egger M, Probst S, Messmann H, Moehler M, Fischbach W, Hartmann JT, Mayer F, Höffkes HG, Koenigsmann M, Arnold D, Kraus TW, Grimm K, Berkhoff S, Post S, Jäger E, Bechstein W, Ronellenfitsch U, Mönig S, Hofheinz RD. Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial. JAMA Oncol. 2017;3:1237-1244.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 417]  [Cited by in RCA: 378]  [Article Influence: 42.0]  [Reference Citation Analysis (4)]
52.  Al-Batran SE, Goetze TO, Mueller DW, Vogel A, Winkler M, Lorenzen S, Novotny A, Pauligk C, Homann N, Jungbluth T, Reissfelder C, Caca K, Retter S, Horndasch E, Gumpp J, Bolling C, Fuchs KH, Blau W, Padberg W, Pohl M, Wunsch A, Michl P, Mannes F, Schwarzbach M, Schmalenberg H, Hohaus M, Scholz C, Benckert C, Knorrenschild JR, Kanngießer V, Zander T, Alakus H, Hofheinz RD, Roedel C, Shah MA, Sasako M, Lorenz D, Izbicki J, Bechstein WO, Lang H, Moenig SP. The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the German AIO/CAO-V/CAOGI. BMC Cancer. 2017;17:893.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 195]  [Cited by in RCA: 180]  [Article Influence: 20.0]  [Reference Citation Analysis (2)]
53.  Marrelli D, Carbone L, Fusario D, Petrioli R, Poto GE, Grassi G, Piagnerelli R, Piccioni SA, Ricci C, Bianco MT, Mazzei MA, Lazzi S, Roviello F. Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Malignancies with Palliative and Bidirectional Intent. Cancers (Basel). 2025;17:1938.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 6]  [Reference Citation Analysis (0)]
54.  Marrelli D, Pedrazzani C, Neri A, Corso G, DeStefano A, Pinto E, Roviello F. Complications after extended (D2) and superextended (D3) lymphadenectomy for gastric cancer: analysis of potential risk factors. Ann Surg Oncol. 2007;14:25-33.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 59]  [Cited by in RCA: 65]  [Article Influence: 3.4]  [Reference Citation Analysis (11)]
55.  Kulig J, Popiela T, Kolodziejczyk P, Sierzega M, Szczepanik A; Polish Gastric Cancer Study Group. Standard D2 versus extended D2 (D2+) lymphadenectomy for gastric cancer: an interim safety analysis of a multicenter, randomized, clinical trial. Am J Surg. 2007;193:10-15.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 72]  [Cited by in RCA: 71]  [Article Influence: 3.7]  [Reference Citation Analysis (0)]
56.  Yonemura Y, Wu CC, Fukushima N, Honda I, Bandou E, Kawamura T, Kamata T, Kim BS, Matsuki N, Sawa T, Noh SH; East Asia Surgical Oncology Group. Randomized clinical trial of D2 and extended paraaortic lymphadenectomy in patients with gastric cancer. Int J Clin Oncol. 2008;13:132-137.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 70]  [Cited by in RCA: 72]  [Article Influence: 4.0]  [Reference Citation Analysis (4)]
57.  Wu L, Ge L, Qin Y, Huang M, Chen J, Yang Y, Zhong J. Postoperative morbidity and mortality after neoadjuvant chemotherapy versus upfront surgery for locally advanced gastric cancer: a propensity score matching analysis. Cancer Manag Res. 2019;11:6011-6018.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 19]  [Cited by in RCA: 20]  [Article Influence: 2.9]  [Reference Citation Analysis (1)]
58.  Kurokawa Y, Doki Y, Kitabayashi R, Yoshikawa T, Nomura T, Tsuji K, Goto M, Cho H, Hihara J, Hiki N, Nunobe S, Mizusawa J, Boku N, Terashima M. Short-term outcomes of preoperative chemotherapy with docetaxel, oxaliplatin, and S-1 for gastric cancer with extensive lymph node metastasis (JCOG1704). Gastric Cancer. 2024;27:366-374.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 1]  [Cited by in RCA: 26]  [Article Influence: 13.0]  [Reference Citation Analysis (1)]
59.  Deng Y, He LJ, Li X. Robotic versus laparoscopic gastrectomy for gastric cancer in asia: A meta-analysis of short-term outcomes from six randomized controlled trials. Eur J Surg Oncol. 2025;51:110298.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 2]  [Reference Citation Analysis (1)]
60.  Du R, Wan Y, Shang Y, Lu G. Robotic Versus Laparoscopic Gastrectomy for Gastric Cancer: The Largest Systematic Reviews of 68,755 Patients and Meta-analysis. Ann Surg Oncol. 2025;32:351-373.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 1]  [Cited by in RCA: 26]  [Article Influence: 26.0]  [Reference Citation Analysis (0)]
61.  Seo HS, Shim JH, Jeon HM, Park CH, Song KY. Postoperative pancreatic fistula after robot distal gastrectomy. J Surg Res. 2015;194:361-366.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 49]  [Cited by in RCA: 48]  [Article Influence: 4.4]  [Reference Citation Analysis (6)]
62.  Nomura M, Kunisaki C, Akiyama H, Matsuda G, Otsuka Y, Ono H, Takahashi M, Shimada H. Surgical outcome of para-aortic lymph node dissection preserving neural tissue based on anatomical evaluations. J Gastrointest Surg. 2005;9:781-788.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 5]  [Cited by in RCA: 6]  [Article Influence: 0.3]  [Reference Citation Analysis (0)]
63.  Liu Q, Meng C, Cao S, Liu X, Tian Y, Li Z, Zhong H, Sun Y, Yu J, Zhou Y. Comparison of short- and long-term outcomes of robotic versus laparoscopic gastrectomy for locally advanced gastric cancer after neoadjuvant therapy: a high-volume center retrospective study with propensity score matching. Surg Endosc. 2025;39:2814-2827.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 5]  [Reference Citation Analysis (1)]
64.  Zhang M, Yang H, Fu T, Meng M, Feng Y, Qu C, Li Z, Xing X, Li W, Ye M, Li S, Bu Z, Jia S. Liquid biopsy: circulating tumor DNA monitors neoadjuvant chemotherapy response and prognosis in stage II/III gastric cancer. Mol Oncol. 2023;17:1930-1942.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 16]  [Reference Citation Analysis (3)]
65.  Mathias-Machado MC, de Jesus VHF, Jácome A, Donadio MD, Aruquipa MPS, Fogacci J, Cunha RG, da Silva LM, Peixoto RD. Claudin 18.2 as a New Biomarker in Gastric Cancer-What Should We Know? Cancers (Basel). 2024;16:679.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 44]  [Cited by in RCA: 62]  [Article Influence: 31.0]  [Reference Citation Analysis (3)]
66.  Dong D, Fang MJ, Tang L, Shan XH, Gao JB, Giganti F, Wang RP, Chen X, Wang XX, Palumbo D, Fu J, Li WC, Li J, Zhong LZ, De Cobelli F, Ji JF, Liu ZY, Tian J. Deep learning radiomic nomogram can predict the number of lymph node metastasis in locally advanced gastric cancer: an international multicenter study. Ann Oncol. 2020;31:912-920.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 360]  [Cited by in RCA: 328]  [Article Influence: 54.7]  [Reference Citation Analysis (13)]
Footnotes

Peer review: Externally peer reviewed.

Peer-review model: Single blind

Specialty type: Oncology

Country of origin: Italy

Peer-review report’s classification

Scientific quality: Grade B, Grade B, Grade B, Grade B, Grade D

Novelty: Grade B, Grade B, Grade B, Grade B, Grade B

Creativity or innovation: Grade B, Grade B, Grade B, Grade B, Grade B

Scientific significance: Grade B, Grade B, Grade B, Grade B, Grade D

P-Reviewer: Chisthi MM, Associate Professor, MD, Professor, India; Fan QX, MD, China; Ghannam WM, Additional Professor, MD, Professor, Egypt S-Editor: Fan M L-Editor: A P-Editor: Zhao YQ

Write to the Help Desk